Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 4/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.30 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.30 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.30 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.30 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30979873 | 0.72 | EGFR (0.44) | EGFR | |
| SCHEMBL34463538 | 0.72 | ENPP1 (0.47) | EGFRENPP1 | |
| SCHEMBL27795278 | 0.72 | ENPP1 (0.47) | EGFRENPP1 | |
| SCHEMBL18655511 | 0.68 | EGFR (0.42) | EGFRENPP1 | |
| SCHEMBL29834813 | 0.67 | EGFR (0.41) | EGFRENPP1 | |
| SCHEMBL30001688 | 0.67 | ENPP1 (0.57) | KDM4EALDH1A1EGFRPDGFRBPDGFRA | |
| SCHEMBL30979890 | 0.62 | EGFR (0.43) | KDM4EALDH1A1EGFRPDGFRBPDGFRA | |
| SCHEMBL27987996 | 0.62 | PDGFRB (0.61) | EGFRPDGFRBPDGFRA | |
| SCHEMBL18660016 | 0.62 | TSHR (0.40) | ALDH1A1EGFRPDGFRBPDGFRAENPP1 | |
| SCHEMBL30979886 | 0.61 | EGFR (0.42) | KDM4EALDH1A1EGFRPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | VORONOI INC. (KR) | 2024-07-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246940-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | ERBB2, EGFR, ERBB3 | KDM4E 3031/4885ALDH1A1 3064/4885EGFR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.